IRB #

STUDY00021299

Title

[Advarra - IAA] AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)

Principal Investigator

Aimee Pierce

Study Purpose

The AHEAD 3-45 Study is a four-year clinical trial evaluating a potential treatment to slow early brain changes and help prevent symptoms associated with Alzheimer’s disease.

Medical Condition(s)

Memory loss, memory problems, Alzheimer's disease, preclinical Alzheimer’s Disease, dementia

Eligibility Criteria

Healthy adults ages 55-80.
Have not been diagnosed with Alzheimer’s disease or another dementia.
Have a study partner, either a close relative or friend, who will participate in one study visit per year.
Have elevated or intermediate levels of amyloid in their brain found by imaging as part of the study.

Healthy Volunteers Needed

Yes

Placebo Chance

50% (1 in 2) chance of receiving placebo.

Duration of Participation

4 years

Minors Included

No

Contact

503-494-7647
adresearch@ohsu.edu

Sponsor

National Institute on Aging (NIA) and Eisai Inc.

Recruitment End

10/31/2023

Compensation Provided

Yes

Compensation

Participants will be paid $50 for each completed study visit. They will also receive $50 for each completed amyloid PET scan, tau PET scan, and MRI scan.


Go Back